We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+1.16%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$167M
AUM Growth
-$2.8M
Cap. Flow
+$3.4M
Cap. Flow %
2.04%
Top 10 Hldgs %
73.09%
Holding
35
New
13
Increased
8
Reduced
5
Closed
8

Top Buys

1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$8.68M
2
BSTC
BioSpecifics Technologies Corp.
BSTC
+$7.85M
3
VCYT icon
Veracyte
VCYT
+$6.73M
4
CDNA icon
CareDx
CDNA
+$5.74M
5
VYNT
Vyant Bio, Inc. Common Stock
VYNT
+$4.54M

Top Sells

1
PCRX icon
Pacira BioSciences
PCRX
+$14.1M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$10.3M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$8.59M
4
VCEL icon
Vericel Corp
VCEL
+$5.85M
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$3.71M

Sector Composition

1 Healthcare 98.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIVE
1
DELISTED
VIVEVE MED INC
VIVE
$19.1M 11.47%
3,850
– –
BSTC
2
DELISTED
BioSpecifics Technologies Corp.
BSTC
$16.7M 10.02%
385,954
+174,584
+83% +$7.85M
APEN
3
DELISTED
Apollo Endosurgery, Inc.
APEN
$14.3M 8.59%
2,560,314
+195,607
+8% +$891K
VNDA icon
4
Vanda Pharmaceuticals
VNDA
$327M
$13.5M 8.06%
885,000
+585,000
+195% +$8.68M
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$400M
$12.8M 7.68%
218,434
-171,566
-44% -$8.59M
BDSI
6
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$10.8M 6.45%
3,645,491
-221,909
-6% -$613K
SCTL
7
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$9.71M 5.82%
1,170,878
-452,359
-28% -$3.71M
CPIX icon
8
Cumberland Pharmaceuticals
CPIX
$102M
$9.62M 5.77%
1,306,911
+34,720
+3% +$255K
VCYT icon
9
Veracyte
VCYT
$4.72B
$8.07M 4.83%
1,235,147
+905,147
+274% +$6.73M
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.33M 4.39%
2,350,000
-1,137,209
-33% -$3.2M
CDNA icon
11
CareDx
CDNA
$2.05B
$6.75M 4.05%
+920,000
New +$5.74M
NVLN
12
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$5.29M 3.17%
1,694,717
-131,647
-7% -$633K
CORV
13
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$4.95M 2.97%
3,195,692
+328,907
+11% +$528K
CTIC
14
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4.92M 2.95%
1,834,838
+841,838
+85% +$2.47M
ALIM
15
DELISTED
Alimera Sciences
ALIM
$4.74M 2.84%
237,327
+205,512
+646% +$4.01M
VYNT
16
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$3.3M 1.98%
+11,907
New +$4.54M
SBBP
17
DELISTED
Strongbridge Biopharma plc.
SBBP
$2.5M 1.5%
+344,282
New +$2.15M
STDY
18
DELISTED
SteadyMed Ltd
STDY
$2.29M 1.37%
+617,725
New +$2M
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.09M 1.25%
+5,000
New +$1.79M
NEOS
20
DELISTED
Neos Therapeutics, Inc
NEOS
$1.43M 0.86%
+140,000
New +$1.34M
ACER
21
DELISTED
Acer Therapeutics Inc
ACER
$1.39M 0.83%
+100,000
New +$1.63M
FRTX
22
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.24M 0.74%
+2,147
New +$1.41M
VSTM icon
23
Verastem
VSTM
$530M
$691K 0.41%
+18,750
New +$847K
NGNE icon
24
Neurogene
NGNE
$744M
$476K 0.29%
+2,025
New +$474K
ADMA icon
25
ADMA Biologics
ADMA
$2.02B
$217K 0.13%
+67,647
New +$189K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Stonepine Capital Management held 35 positions worth $167M, down 1.7% from $170M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Stonepine Capital Management's Q4 2017 filing shows 13 new, 8 increased, 5 reduced and 8 closed positions. Its largest new stake was CareDx: 920,000 shares worth $6.75M. The largest sale was Pacira BioSciences, an estimated $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

  • Stonepine Capital Management's largest Q4 2017 buy was CareDx: 920,000 shares worth $6.75M.
  • Stonepine Capital Management added most to Vanda Pharmaceuticals in Q4 2017, an estimated $8.68M increase.
  • Stonepine Capital Management's biggest Q4 2017 reduction was Enanta Pharmaceuticals, cutting an estimated $8.59M.
  • Stonepine Capital Management fully exited Pacira BioSciences in Q4 2017, selling an estimated $14.1M.
  • Stonepine Capital Management's ten largest holdings make up 73% of its $167M portfolio in Q4 2017.
  • Stonepine Capital Management opened 13 new positions and closed 8 in Q4 2017.
  • Stonepine Capital Management's portfolio value fell 1.7% quarter-over-quarter to $167M.

Based on Stonepine Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.